Skip to main navigation
Overview
Newsroom
News Releases
Corporate Statements
Multimedia Resources
Events & Presentations
Events
Presentations
Financials
SEC Filings
Annual Reports
Stock Information
Stock Quote & Chart
Analyst Coverage
Investor FAQs
Corporate Governance
Governance Documents
Committee Composition
Leadership
Code of Business Conduct
Corporate Responsibility
Contact the Board
Top bar
Biogen.com
Information Request
Sign up for Alerts
Search
Search
Search
SEC Filings
Form 4
Asset
Aducanumab EMBARK study design at CTAD 2020
Aducanumab EMBARK study design at CTAD 2020
751.9 KB
News
Biogen to Webcast Prerecorded Presentation on Aducanumab Embark Study Design and Live Q&A from CTAD on November 4, 2020
News
Biogen to Present Positive Phase 2 Systemic Lupus Erythematosus Data at American College of Rheumatology 2020 Meeting
News
European Medicines Agency Accepts Biogen’s Aducanumab Marketing Authorization Application for Alzheimer's Disease
Asset
Biogen Reports Q3 2020 Results
Biogen Reports Q3 2020 Results
232.7 KB
Asset
Q3 2020 Biogen Earnings Presentation
Q3 2020 Biogen Earnings Presentation
2.5 MB
News
Biogen Reports Q3 2020 Results
SEC Filings
Form 8-K
SEC Filings
Form 10-Q
Pagination
Previous page
‹‹
Page 2
Next page
››
Filter by gallery
No facets
Your selection
Clear all
2020
Remove
Filter by category
Filter by category
Filter by category
Filter by category
Filter by type
Filter by tags
Filter by form group
Filter by content year
(-)
2020
(148)
Filter by content type
SEC filing
(66)
News
(53)
Asset
(16)
Event
(13)
Tools
Print Page
Stockholder Communications
E-mail Alerts
FAQs
Facebook
Twitter
LinkedIn
Google+
